MBOT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Microbot Medical Inc (MBOT) is not a strong buy for a beginner investor seeking long-term growth at this time. While the company has promising technology and positive analyst sentiment, the lack of significant financial growth, bearish technical indicators, and weak trading signals suggest waiting for clearer signs of upward momentum before investing.
The technical indicators for MBOT are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 46.45, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 2.265 and resistance at 2.617.
The LIBERTY® Endovascular Robotic System has received FDA clearance and is the only single-use, remotely operated robotic platform for peripheral vascular procedures.
Recent announcements of successful Limited Market Release and plans for Full Market Release suggest potential for market adoption.
Analyst coverage initiated with a Buy rating and a $5 price target, citing competitive advantages and faster commercial traction.
Financial performance remains weak, with no revenue growth and negative EPS (-0.
in Q4
Technical indicators are bearish, and the stock is experiencing a pre-market decline of -1.26%.
No significant hedge fund or insider trading activity to indicate strong institutional confidence.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$3.46M, which improved slightly by 2.12% YoY. EPS dropped significantly by -75% YoY to -0.05, reflecting poor profitability. Gross margin remained at 0%.
B. Riley initiated coverage with a Buy rating and a $5 price target, citing the company's competitive edge as the only FDA-cleared robotic system for peripheral vascular procedures and its disposable model that bypasses capital equipment procurement.
